pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 14·1 min read
save

Major digital health firms stay out of Medicare's chronic care ACCESS pilot

May 14, 2026·read at STAT ↗Neutral

The latest STAT Health Tech newsletter reports that the biggest players in digital health are not participating in Medicare's ACCESS pilot, a program designed to test chronic-care solutions for Medicare beneficiaries.

The pilot, launched by the Centers for Medicare & Medicaid Services, seeks to evaluate how remote monitoring, mobile apps and other digital tools can improve outcomes and reduce costs for patients with long-term conditions.

While smaller innovators are joining the experiment, large firms have opted out, citing uncertainty around reimbursement models and regulatory pathways.

The newsletter also notes that Isomorphic, a digital-health startup, recently secured a sizable funding round, highlighting continued investor interest despite the hesitation of larger companies.

Analysts suggest that the lack of participation by major vendors could limit the pilot's ability to generate scalable insights, and may signal broader challenges in aligning Medicare policy with the digital health market.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Why big digital health players are missing from Medicare’s chronic care experiment”

read at STAT ↗
479 words · retrieved May 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Psychiatry & CNS2CAR-TDuchenne Muscular DystrophyGene Therapy (AAV)

related stories

  • Sep 21Mikhail, Davis on board with regulatory framework tailored to rare disease therapiesBioSpace
  • Aug 14After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?Fierce Biotech
  • Aug 54 potential biotech M&A targets, plus a pretty sure bet from J&JBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • May 14Makary’s departure and Cassidy’s tenuous Senate seatSTAT